#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Frontotemporal dementia Hypochondroplasia T-cell type acute leukaemia Primary amyloidosis Arrhythmogenic right ventricular dysplasia Cognitive disorder Glioblastoma multiforme Thermal burn Enteritis Hairy cell leukaemia Mycobacterium abscessus infection Crigler-Najjar syndrome Familial dilated cardiomyopathy Breast angiosarcoma metastatic Biotinidase deficiency More trials…

    Learn about Rare Diseases

    Haemophilia A without inhibitors – Treatment Prolymphocytic leukaemia – Diagnostics Gastrointestinal stromal tumour – Treatment Leukoencephalopathy – Diagnostics Chondrosarcoma – Life with Disease Retinoblastoma – Treatment Activated PI3 kinase delta syndrome – Basic Information Glomerulonephritis rapidly progressive – Life with Disease Sarcoma Marfan’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxygen Ph.eur. Sodium Phosphate Hydroxocobalamin Peginterferon Beta-1A Bgb-15025 Citrate Tadalafil Camlipixant Tinzaparin Vo659 Olmesartan Medoxomil XELAFASLATIDE Caspofungin Maraviroc Ozanimod Hydrochloride Tumor Necrosis Factor-Alpha Defactinib Pf-06835375 Nofazinlimab Alendronic Acid S227928 More therapies…

    Learn about Your Condition

    Epileptic encephalopathy Embolism venous Synovitis Pancoast's tumour Endocrine ophthalmopathy Gallbladder cancer Rhabdoid tumour of the kidney Tardive dyskinesia Circulatory collapse Renal impairment Craniosynostosis Perinatal depression Thromboembolectomy Aicardi-Goutieres syndrome Adenocarcinoma of colon More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Simeonidi Alex 2, Thessaloniki, 546 39, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atezolizumab
    Belgium Czechia France Germany Greece Ireland +3

  • Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Niraparib Tosilate Monohydrate
    • Pembrolizumab
    Belgium Bulgaria France Germany Greece Hungary +8

  • Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate Ph. Eur.
    • Montelukast Sodium
    • Dexamethasone Sodium Phosphate
    Czechia Denmark France Germany Greece Hungary +5

  • Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • Bemarituzumab
    • Fluorouracil
    • Folinic Acid
    Belgium Bulgaria Czechia Denmark Estonia France +12

  • Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone Acetate
    Belgium Czechia Denmark France Germany Greece +5

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicle centre lymphoma follicular grade I II – III refractory
    Investigated Drugs:
    • Epcoritamab
    • Lenalidomide
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +8

  • Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Human Normal Immunoglobulin
    • Lenalidomide
    Austria Belgium Czechia Finland France Germany +8

  • Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    Austria Belgium France Germany Greece Hungary +6
Previous Page
1 … 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!